Search

By Industry Solutions (2)
By Phase (1)
By Molecule Type (1)
By Therapeutic Area (3)
Covance Events (9)
Geography (3)
Keywords (10)

Filters

Showing results 689 - 704 of 91813 for .

Showing results 689 - 704 of 91813 for .

Investing in the Future of Precision Medicine
In previous posts on this blog, our scientists have described the current state of precision medicine, particularly how it relates to companion diagnostics (CDx) and immuno-oncology. As an enterprise, we have been focused on this area of medicine essentially from the beginning, more than 20 years ago
An Analytical Approach to Enhance Recruitment of Rheumatoid Arthritis Patients
No single blood test or physical finding alone can confirm the diagnosis of rheumatoid arthritis (RA). However, two tests that detect markers of inflammation are often ordered when RA is suspected: erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP). Other common tests include rheumatoid factor and anti-CCP antibodies
Understanding the Power of Natural Killer Cells and New Nonradioactive Assay Approaches
Natural killer (NK) cells first earned their title as "killers" nearly 40 years ago when researchers observed the rapid immune response of these lymphocytes as they destroyed host cells infected with a virus or tumor cells. It seemed that NK cells could attach spontaneously without prior activation.
The 7 Essentials of Successful Health Economic Communication
The role of health economic data has never been more important. Learn about the seven essentials for the successful communication of health economic data to help ensure your audiences hear, understand and act upon the information.
Stratification of Metastatic Colorectal Cancer Patients Using DNA and RNA Sequencing and In-Silico Prediction of Tumor Antigens for Consideration in Immunotherapy
Colorectal cancer (CRC) is the third most common type of cancer among both men and women in the United States. Although chemotherapy, radiation and targeted therapies can improve survival rates, recent studies have shown the potential benefit of immunotherapies to improve outcomes for patients with advanced CRC. Targeted therapies that use monoclonal antibodies (mAbs) to EGFR have been shown to benefit some CRC patients. Until recently, KRAS has been the only predictive biomarker for...
Meta-Analysis of Genomic Aberrations Identified in CTCs and ctDNA in Triple Negative Breast Cancer
Technological innovation and scientific advances in understanding cancer at the molecular level have accelerated the discovery and development of both diagnostics and therapeutics. Circulating tumor cells (CTCs) and plasma circulating tumor DNA (ctDNA) are non-invasive prognostic markers that have been associated with metastatic and aggressive disease. Both CTCs and ctDNA allow molecular characterization of a tumor that is inaccessible or too risky to biopsy. The analysis of genomic...
Synergistic Effects of Promoter Associated DNA Methylation and Genetic Alterations to Better Understand Oncogenic Gene Expression Profiles
The emergence of Next Generation Sequencing (NGS) along with computational biology has broadened the scope in which diverse cellular processes can be interrogated. While there has been considerable progress in understanding the impact of genetic and epigenetic mechanisms in tumorigenesis using whole genomic, epigenomic and transcriptional analysis by NGS, there has been little consideration of the importance of interplay between these processes. We performed a comparative analysis of array...
Investigation of Genetic Architecture of Multiple Myeloma by Next Generation Sequencing
Myeloma is a genetically heterogeneous disease and is sub-classified based on the presence of structural variants and genetic mutations. Structural variants/copy number changes are historically identified by traditional methods such as karyotyping and fluorescence in situ hybridization (FISH). Although microarray based genome wide analyses greatly improve the resolution of structural variation, they may be limited by probe density.
Reducing Turnaround Time for Oncology Clinical Trials with Integrated APH and Biomarkers Solutions
Reducing Turnaround Time for Oncology Clinical Trials with Integrated APH and Biomarkers Solutions
Biomarker Development for Parkinson's Disease
Two page article detailing the development of a biomarker for Parkinson's Disease.
Creating a Robust Reimbursement Support Program for Biosimilars
Learn how a robust reimbursement program is critical to launching a successful biosimilar product.
Country Selection for Your Clinical Study: There is a Method to the Madness
Two page article on why choosing where to conduct global clinical trials is a strategic decision that can impact an entire drug development program.
Single-Laboratory Validation Study of a Method for Screening and Identification of Phosphodiesterase Type 5 Inhibitors in Dietary Ingredients and Supplements Using Liquid ...
A single-laboratory validation study of a method for screening and identification of phosphodiesterase type 5 (PDE5) inhibitors in dietary ingredients and supplements is described. PDE5 inhibitors were extracted from the samples using a 50:50 (v/v) mixture of acetonitrile and water and centrifuged. Supernatant was diluted, filtered, and analyzed by LC - high-resolution MS. Data were collected in MS acquisition mode that combined full-scan MS experiment with all-ion fragmentation and...
PHASE I cGMP DRUG MANUFACTURING AT THE CRU: Three Key Benefits
Discover Three Key Benefits of using a current good manufacturing practice (cGMP) pharmacy at your clinical research unit (CRU) for Phase I drug manufacturing: quality and safety, timeline reduction and cost efficiency. Learn key points to help make informed decisions about the design, monitoring and control of your Phase I drug manufacturing.
Covance Central Laboratory Services Again Ranks #1 in Global Investigator Satisfaction Survey
The importance of the contributions by investigator sites to the success of a clinical trial cannot be overstated. Investigator sites represent the starting point for the patient sample life cycle, and their engagement in the trial is a key limiting factor for meeting patient enrollment milestones. A recent independent study by the Life Sciences Strategy Group shed light on the perceptions and behavioral drivers of a global cross-section of clinical trial investigator sites.
Gaining a Critical Advantage with Stakeholder Research
Discover why best-in-class companies, both small and large, are increasingly turning to early stakeholder to guide their development strategy, inform crucial decision points and increase their commercial potential.